Get started

Canada

Tilray most likely to hit ~$174aicody.com Company Summary Tilray, Inc. (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in ten countries spanning five continents. Tilray has reported financial results for second quarter of 2018 and six months ended June 30, 2018. “We are very pleased with our strong start to 2018. Tilray is well-positioned to continue to pioneer the development of the global medical cannabis market and to become a leader in the adult-use cannabis market in Canada,” said Mr. Brendan Kennedy, President and Chief Executive Officer of Tilray. “In the second quarter, we generated significant revenue growth as a result of our global strategy, our multinational distribution network and our commitment to research, innovation, quality and operational excellence. Second Quarter 2018 Financial Highlights Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales. Total kilogram equivalents sold increased 745 kilograms to 1,514 kilograms, or 97%, compared to the prior year. Average net selling price per gram increased from $6.20 to $6.38 (C$8.12 to C$8.36) for the three months ended June 30, 2017 and 2018, respectively. The increase was primarily due to growth in higher potency product and extract sales, partially offset by an increase in wholesale revenues. Net loss for the quarter was $12.8 million compared to $2.4 million for the second quarter of 2017. Net loss includes non-cash stock compensation charges of $5.6 million compared to a $35 thousand charged in the prior year period. Adjusted EBITDA was a loss of $4.7 million compared to a loss of $1.9 million the second quarter last year. The increased net loss and Adjusted EBITDA decline was primarily due to the increase in operating expenses related to continued growth, expansion of international teams, and costs related to financing and the initial public offering (“IPO”). Business Highlights in 2018 to date: Successfully completed IPO in July whereby 10.350 million shares of Class 2 Common Stock were sold at an initial price to the public of $17.00 per share. The Company received net proceeds of $163.6 (C$216.9) million after the underwriting discount. Net proceeds will be used to fund the build out of cultivation and processing capacity, repay outstanding principal and interest under the Privateer Holdings debt facilities, and for future acquisitions and working capital. Prior to the IPO, completed Series A funding of $55.0 (C$69.2) million from leading institutional investors. Signed agreements to supply cannabis to adult-use consumers in seven Canadian provinces and territories (British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, the Yukon territory and the Northwest Territories). Entered into a strategic agreement with Sandoz Canada, a division of Novartis, to collaborate on the creation and sale of co-branded and co-developed non-combustible medical cannabis products. Signed agreement with Shoppers Drug Mart Inc., Canada’s largest pharmacy chain with more than 1,200 pharmacies and expect to supply Tilray products following approval of Shoppers’ application to become a Licensed Producer. Signed binding letter of intent with Pharmasave, one of Canada’s leading independent pharmacy chains with more than 650 pharmacies, which Tilray anticipates will allow it to supply Pharmasave stores with Tilray products contingent upon a change in laws that permits Canadian pharmacies to distribute medical cannabis to patients. Completed exports to Argentina, South Africa and the United Kingdom, making Tilray products available in 11 countries on five continents. Launched High Park Holdings Ltd., Tilray’s wholly owned subsidiary formed to serve the pending adult-use market in Canada with a broad-based portfolio of cannabis brands and products. Announced the launch of the CANACA™ brand, a new cannabis brand celebrating Canadian roots, values and this historical moment in Canada as the country becomes the world’s first G7 nation to federally legalize cannabis through adult-use legalization. Announced clinical study results of Tilray® 2:100 product showed promise in Canada’s first pediatric study of mixed THC/CBD medical cannabis oil for children with drug-resistant epilepsy. Statistics Shares Outstanding: 76.5M Avg Daily Vol: 8.5M Market Cap: 14.08B 52-Week High: $151.18 52-Week Low: $20.10 Forward PE: NA Annual Div/Dividend Yield: $0.00 / 0.00% Annual Rev: 23.1M Inst Own: 0.0% 1-Month Return: NA 3-Month Return: NA Next Earnings Report Date: 08/29/2018 Earnings ESP: -0.18 Revenue Per Employee: $85,912 Money Flow Ratio: 1.08% Profitability Revenue Growth: 62.5% (Sector Average 3.3%) Gross Margin: 53.0% (Sector Average 62.4%) Return on Equity: NA (Sector Average -19.2%) Net Margin: -52.9% (Sector Average -10.4%) Debt Current Ratio: 1.1 (Sector Average 2.9) Debt-to-Capital: 230.5% (Sector Average 25.8%) Interest Funding: -12.5% (Sector Average 0.3%) Interest Coverage: -11.6 (Sector Average -4.7) Dividend Dividend Growth: NA (Sector Average 5.5%) Dividend Payout: NA (Sector Average 66.7%) Dividend Coverage: NA (Sector Average 2.1) Dividend Yield: NA (Sector Average 0.00%) Top Peer Companies Akcea Therapeutics Inc (AKCA) Akorn Inc (AKRX) American Cannabis Company Inc (OTCMKTS: AMMJ) Amphastar Pharmaceuticals Inc (AMPH) Aphira Inc (TSE: APH) Aurora Cannabis Inc (TSE: ACB) Cambrex Corp (CBM) CannaRoyalty Corp (CNSX: CRZ) Canopy Growth Corp (CGC) Corcept Therapeutics Inc (CORT) Cronos Group Inc (CRON) Emergent BioSolutions Inc (EBS) Hydropothecary Corp (TSE: HEXO) Innoviva Inc (INVA) Maricann Group Inc (CNSX: MARI) Medmen Enterprises Inc (CNSX: MMEN) MedReleaf Corp (MEDFF) OPKO Health Inc (OPK) Pacira Pharmaceuticals Inc (PCRX) Theravance Biopharma Inc (TBPH) VIVO Cannabis Inc (ABCCF) 12 Month Price Target Mean: USD$115.05 High: USD$174.33 Low: USD$90.32 Revenue Growth Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales. Earnings Surprise Positive (+18.4%)
NASDAQ:TLRYLong
by aicody
2
USDCAD Trading PlanThe fundamentals that move the Canadian Dollar the past week or so were the updates on the NAFTA deal. If a deal struck, Canadian will definitely strengthen. However, the Commodity Market is an important catalyst as well specifically Oil. US-China Trade war somewhat affecting market sentiment and the energy market is no different. The market sentiment at the moment is fragile. Having said that though, technically we have setups and if the market players decided to dump their CAD longs that I would hope will be illustrated in the chart as a bullish engulfing candle, then I will be a CAD Bull. Should there be an update of the NAFTA deal specifically hinting or confirming a NAFTA deal will be struck, I will short the pair and target according to the daily range.
by sufiansaid
The USD Rallies Against CAD on Good US Data and NAFTAUSDCAD has been extremely bullish lately, on extremely strong manufacturing data today. It has retraced all of its losses which were caused by CAD strength due to hopes for successful NAFTA negotiations. Currently, Trump has made numerous hints that Canada may not even be a part of NAFTA anymore, and the Canadian Prime Minister, Justin Trudeau has fired back saying that he’d rather not be a part of NAFTA than have a deal that didn’t benefit Canada. The current price of USDCAD is 1.3178, which is dangerously close to the upper bound of the Kovach Reversals indicator at 1.3186. We should definitely see some resistance at this level. Technical analysis for USDCAD is as follows. Volatility is lower than usual, but not to an extreme. The RSI indicates that we are in a bull trend, but not overbought yet. The MACD is above the signal line, but not to an extreme. This suggests we may have more room to appreciate. USDCAD is under the 50 period SMA, which is currently at 1.31, indicating bearishness. The ADX does not indicate a trend, i.e. we are ranging. Bull Score: 2 Bear Score: 1 Ranging Score: 2 The technical analysis for USDCAD intraday is very strong. We see many indications of a strong bull trend. It would be wise to buy on a dip. The technicals for USDCAD intraday are as follows. Volatility is slightly higher than usual, but not to an extreme. The RSI indicates that we are in a bull trend, but not overbought yet. The MACD suggests that we are in a bullish phase but not overbought yet. USDCAD intraday is above the 50 period SMA by quite a bit, suggesting that we are overbought. Also, USDCAD intraday is above the 100 period SMA by quite a bit, suggesting that we are overbought. Finally, the 50 period SMA is even with the 100 period SMA, indicating longer term ranging. The ADX indicator is at 64, which suggests a strong bull trend for USDCAD intraday. Intraday, the Kovach OBV and the Kovach Chande are quite strong, necessitating that one wait for a pullback before entering a trade in this product.
Long
by quantguy
Significant Reversal in WEF?1. Daily chart shows "Three White Soldiers" or three bullish candles. Price is closed out quite well. Three such candles haven't been seen before at a low point in the downtrend. This suggests that this may be a significant low point. 2. Weekly chart show a bullish hammer followed by a week with a higher high and higher low. 3. On both time frames, bullish price action is happening at the lower bollinger band . Go long at 2.40. Stop Loss at 2.21. Projected price range is 2.75-2.85. Give it a little extra room, in case of a immediate pull-back.
TSX:WEFLong
by AnishBadwe
SHOP - The w[E]ed-[Commerce] solution from CANADA So you should know this buy now www.cbc.ca And if you are from Ontario and over 19 years old, I bet you also know what happens on October 17, 2018. www.ontario.ca Shopify Inc. (Nasdaq: SHOP) is a company that’s about to make billions from the end of marijuana prohibition without ever touching the leaf. It’s the online retailer – not Amazon.com Inc. (Nasdaq: AMZN) – that just inked a contract to provide an e-commerce platform for a major Canadian cannabis retailer. You see, when Canada goes fully legal later in summer 2018, pot companies will want to sell (and their customers will want to buy) their wares online. Makes sense. And the great news for investors in Shopify? The Ontario Cannabis Retail Corp. (OCRC) – the government agency in charge of sales in the province – is relying on Shopify, and only Shopify, to make it happen. That’s going to be a huge boon for cannabis investors. Ontario is home to 13.6 million people, with bustling Toronto and its financial sector at the heart of the province. That’s the perfect place to begin cashing in on Canada’s legal weed market, which Deloitte says could hit $8.7 billion over the next few years. But that’s really just the beginning for Shopify. This tech-forward company develops the kind of sophisticated software that allows small retailers to plug into e-commerce platforms like Amazon and sell their stuff. With Shopify’s platform, they can manage orders, collect sales dollars, and send out emails to buyers. Or, if they prefer to go it alone, Shopify can help small retailers build their own online storefront, handle multiple sales channels, and plug into social media for customer outreach. That business model alone qualifies this as a solid choice for investors. Its sales grew an average 85% over the past three years, compared to 26% growth for Amazon during that stretch. Now, OCRC has picked to exclusively use Shopify’s e-commerce platform for cannabis sales online. Shopify’s technology will also be used inside OCRC’s Ontario Cannabis Stores to process transactions and for digital kiosks displaying product information. And Ontario is just the “first mover” here. Many of Canada’s other nine provinces are likely to follow the leader here in choosing the home-grown Shopify (which is based in Ottawa) as their e-commerce partner. That could double Shopify’s total market opportunity there. In fact, Quebec province-based grower Hydropothecary Corp. has already chosen Shopify to help it sell medical marijuana online. Thanks to moves like the OCRC deal, Shopify’s total addressable market stands to exceed $50 billion… As a side note, just imagine if they integrate cryptocurrencies
TSX:SHOPLong
by johntuca
Please BEAR with me : Canada's Inflation and NAFTA dealMy trading belief is that when the price hits the certain range (USDCAD Avg Monthly Range = 300+ish pips), by default it should reverse minimum 60% of the recent move (some of you call it "a retracement") if not the entire move. Candle patterns that I look for in a way to confirm a reversal/retracement is on its way is Piercing Candles or Engulfing Candles. One of the rules I set is that the retracement/reversal bias upon hitting the trading range (in this case, Avg Monthly Range) remain true (the original upside target marked by the red 'X' on the chart) UNTIL one of these candles occurred to invalidate the bias (i.e a bullish retracement bias will be invalidated by a bearish engulfing/piercing candle) The bearish engulfing candle occurred due to the Canadian inflation numbers. If the inflation numbers are that high, the expectation for the Bank of Canada to hike interest rate in September might as well be increased. Moreover, I've read news that the NAFTA deal can be sealed sometime this month which adds more reason to set the Canadian Loonie bias from Bearish to Bullish (BEARISH USDCAD)
Short
by sufiansaid
Penny Stock CYPHER for bullish reversal + FUNDAMENTALSNemaska Lithium TECHNICALS - We have a clear cypher pattern on the long-term chart. And the $0.65-0.70 zone is a strong resistance. This is a strong sign for a trend reversal . FUNDAMENTALS - Nemaska Lithium is a Canadian company sitting on one of the biggest lithium deposits in the world. The First production is expected to be sold in 2019, the last annual report did not reveal any delays in construction of the plant. The company has multiple buyers on contract for future production. There is significant growth potential thanks to cell-phones, electric vehicles and the overall battery market which is expanding very fast and will continue to do so. In addition, the company is backed by SoftBank and the Quebec government. These factors put together make me pick this stock for strong growth on a 6 month-1 year horizon. I encourage you guys to dig deeper on fundamentals as I am not giving to much details here.
NLong
by Tutur
7
USD/CAD (*Selling is a way to go)USD/CAD We were right the previous calls on this pair along and it is about +500 pips. I am expecting USD is on the slides and CAD is due to strengthen as well. So, that makes a perfect pair for a potential SHORT. It may hive and jive around a little bit but sooner or later, it shall slide to 1.285x area. Press "Like" and "Follow". Sonic Disclaimer: The information contained in this presentation is solely for educational purposes and does not constitute investment advice. We may or We may not take the trade. The risk of trading in securities markets can be substantial. You should carefully consider if engaging in such activity is suitable to your own financial situation. We, Sonicr Mastery dot com is not responsible for any liabilities arising from the result of your market involvement or individual trade activities.
Short
by SonicDeejay
2
CVSI - GRAND SLAM - Generational Opportunity - BUY!CVSI is a once in a generation opportunity. The company produces pharmaceutical grade CBD from cannabis. There are too many catalysts to name but the most recent one is that they have applied to move off the pink sheets to the NASDAQ. Also, Canada just legalized cannabis for recreational use and I believe the U.S. will be soon to follow. Lastly, CBD has a lot of promise for health and lifestyle products. CBD is literally being put in to make-up to dog treats. I came home the other night and my wife showed me the new dog treats for my aggressive basset hound. The dog treats had CBD as an ingredient and I checked Amazon to see the reviews. The product had 5 star reviews and everyone loved them. Also, CBD is legal from Hemp in the U.S. BUY BUY BUY! We are beginning the Cycle 3rd Wave now and are making new highs. -AB
OTC:CVSILong
by FibMarketWatch
4
APHQF, Aphria INC. Possible lower levels to look at!Trying my best to keep things simple! Were at the bottom of a wedge, just floating in no mans land. We have the 618 right above, and the 786 below equal distance. On the 4 hour, you can see sell signals at the top of the wedge, creating the last selloff. No buy signals in sight besides the more irrelevant smaller time frames, with the Ichimoku cloud directing bearish. With the 786 level just right there below, Im lead to believe we will fall to that level into a wedge until the end of the year. I do see a bounce coming this week on my yellow brick road, but will ultimately fall to the lower levels. You can see momentum leading bearish as well, with the bolly bands tightening up month by month. Long term this will always do great, but I try to play the bounces with no emotion! Another level to be aware of is the $4.20 area, (ironic). Only if the 786 wedge fails to break out coming November! Happy Trading, Debating, and Speculating! I want everyone to win!
AShort
by ToddGreen